Glioblastoma, Recurrent Brain Neoplasm
Conditions
Brief summary
This pilot clinical trial studies the feasibility of palliative 4pi radiotherapy in treating patients with glioblastoma multiforme that has come back after standard chemoradiation. A new radiotherapy delivery planning system, called 4pi radiotherapy, may help improve radiation delivery by improving dose coverage to the treatment target, while reducing the dose to surrounding normal tissues.
Detailed description
PRIMARY OBJECTIVES: I. To determine the accuracy of dose delivery and patient comfort with treatment time. II. To evaluate normal tissue dose volume statistics and compare to standard planning. OUTLINE: Patients undergo 4pi radiation simulation and planning followed by 5 to 10 daily fractions of 4pi palliative radiotherapy. If an acceptable plan cannot be achieved using 4pi planning, then the patient will be treated with standard radiation therapy planning for palliative re-irradiation. After completion of study treatment, patients are followed up at 6 weeks.
Interventions
RADIATIONPalliative Radiation Therapy
Undergo 4pi palliative radiotherapy
OTHERQuestionnaire Administration
Ancillary studies
Undergo 4pi radiation simulation and planning
Sponsors
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed primary glioblastoma multiforme (GBM) * Patient must have previously undergone standard chemoradiation- 59.4 Gy (1.8 Gy/fraction) or 60 Gy (2.0 Gy/fraction) with concurrent and adjuvant Temodar (temozolomide) * Patient must be diagnosed with recurrent GBM either with biopsy or radiographically * Karnofsky Performance Status (KPS) \>= 70 * Ability to understand and willingness to sign a written informed consent * If a woman is of childbearing potential, a negative serum pregnancy test must be documented; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study treatment and for up to 4 weeks following the study treatment * For the purpose of this study, all women are considered to be of childbearing potential unless they are post-menopausal at least 1 year since last menses), biologically sterile, or surgically sterile (i.e. hysterectomy, bilateral oophorectomy or tubal ligation)
Exclusion criteria
* Patients with active infection * Patients with KPS \< 70 and/or unable to tolerate potentially longer treatment times * Refusal to sign informed consent * Pregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the study treatment * Note: Concurrent and/or adjuvant chemotherapy does not make a patient ineligible; participation in a concurrent treatment protocol does not make a patient ineligible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Accuracy of dose delivery | Up to 6 weeks | The accuracy of dose delivery by 4pi will be compared to standard procedures. Standard quality assurance (QA) procedures will be employed to validate the delivery accuracy of 4pi. Specifically, a MatriXX phantom will be employed to measure the dose in both the coronal and sagittal planes and compared to calculation. Patients with QA results showing gamma passing rates (using 3% and 3 mm dose difference and distance to agreement criteria, respectively) less than 90% in either plane or a maximum single gamma value greater than 2 will not be treated until the source of error is corrected. |
| Normal tissue dose volume | Up to 6 weeks | Statistics will be compared between 4pi and standard planning. Specifically, dose to organs-at-risk (OAR) and planning target volume (PTV) coverage will be compared to assess for improved OAR sparing and improved PTV coverage with 4pi planning. |
| Patient comfort with treatment time, determined by a patient-completed questionnaire completed at the end of each fraction | Up to 10 days | — |
Countries
United States
Outcome results
None listed